• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Analysts bearish on C.R. Bard

Analysts bearish on C.R. Bard

September 7, 2011 By MassDevice staff

C.R. Bard

Analysts at a trio of investment advisory firms downgraded their estimates for C.R. Bard (NYSE:BCR) stock, which hasn’t fared well recently.

Financial researchers at Goldman Sachs (NYSE:GS), Piper Jaffray (NYSE:PJC) and Morgan Keegan all dimmed their views on the stock. Goldman led the way August 9, downgrading BCR shares from “neutral” to “sell.” A week later, Morgan Keenan cut its price target from $115 apiece to $1.07 for the shares but still slapping it with an “outperform” label.

The latest blow came last week, when Piper Jaffray lowered its target to $100 per share, according to Localized USA.

Sign up to get our free newsletters delivered straight to your inbox

BCR shares dipped 4.5 percent in August, opening at $99.80 and closing at $95.26. Shares closed at $91.76 yesterday, down another 3.7 percent, but were up 1.6 percent to $93.24 as of about 11:30 today.

Bard shares have suffered since the company reported paying nearly $185 million legal bill to settle most of the lawsuits against subsidiary Davol Inc.’s hernia repair products. The settlement pushed the company into the red during its fiscal second quarter and sent its share price tumbling on Wall Street.

The Murray Hill, N.J.-based company reported a $47.8 million loss on $725 million in sales during the three months ended June 30, reversing a $124.7 million profit on $673.9 million in sales during the same period last year.

Excluding the settlement, Bard would have posted $141.7 million in net income for the quarter, the company said at the time.

Filed Under: News Well, Product Liability, Wall Street Beat Tagged With: C.R. Bard, Goldman Sachs, Morgan Keenan, Piper Jaffray

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy